Free Trial

Brown Advisory Inc. Sells 153,096 Shares of HealthEquity, Inc. (NASDAQ:HQY)

HealthEquity logo with Medical background

Brown Advisory Inc. lowered its holdings in HealthEquity, Inc. (NASDAQ:HQY - Free Report) by 7.3% in the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,932,930 shares of the company's stock after selling 153,096 shares during the period. Brown Advisory Inc. owned about 2.23% of HealthEquity worth $170,813,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Wealth Enhancement Advisory Services LLC lifted its holdings in shares of HealthEquity by 24.7% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 6,380 shares of the company's stock worth $564,000 after purchasing an additional 1,265 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in shares of HealthEquity by 7,983.6% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 24,655 shares of the company's stock valued at $2,179,000 after purchasing an additional 24,350 shares during the period. GAMMA Investing LLC increased its position in shares of HealthEquity by 25.9% during the 1st quarter. GAMMA Investing LLC now owns 1,571 shares of the company's stock valued at $139,000 after purchasing an additional 323 shares during the period. Pier Capital LLC acquired a new position in shares of HealthEquity during the 4th quarter valued at $8,024,000. Finally, HighTower Advisors LLC increased its position in shares of HealthEquity by 4.8% during the 4th quarter. HighTower Advisors LLC now owns 95,075 shares of the company's stock valued at $9,122,000 after purchasing an additional 4,370 shares during the period. Hedge funds and other institutional investors own 99.55% of the company's stock.

HealthEquity Price Performance

Shares of HQY traded down $3.14 on Wednesday, hitting $99.98. The company's stock had a trading volume of 994,480 shares, compared to its average volume of 867,646. The company has a market capitalization of $8.65 billion, a PE ratio of 72.98, a PEG ratio of 1.59 and a beta of 0.49. The company has a debt-to-equity ratio of 0.50, a current ratio of 4.06 and a quick ratio of 4.06. HealthEquity, Inc. has a fifty-two week low of $65.01 and a fifty-two week high of $116.65. The company has a 50 day moving average price of $100.71 and a 200 day moving average price of $98.41.

HealthEquity (NASDAQ:HQY - Get Free Report) last posted its quarterly earnings data on Tuesday, June 3rd. The company reported $0.97 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.81 by $0.16. HealthEquity had a return on equity of 11.01% and a net margin of 9.80%. The firm had revenue of $330.80 million for the quarter, compared to the consensus estimate of $322.25 million. During the same quarter in the prior year, the business earned $0.80 EPS. On average, research analysts anticipate that HealthEquity, Inc. will post 2.32 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, EVP Michael Henry Fiore sold 1,794 shares of the stock in a transaction on Monday, July 7th. The stock was sold at an average price of $101.73, for a total value of $182,503.62. Following the transaction, the executive vice president owned 53,225 shares of the company's stock, valued at $5,414,579.25. This represents a 3.26% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Jon Kessler sold 134,183 shares of the stock in a transaction on Friday, June 6th. The shares were sold at an average price of $112.08, for a total value of $15,039,230.64. Following the completion of the transaction, the director directly owned 253,510 shares in the company, valued at approximately $28,413,400.80. This trade represents a 34.61% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 291,744 shares of company stock valued at $32,705,007. 1.50% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on HQY shares. Barrington Research lifted their target price on HealthEquity from $112.00 to $125.00 and gave the stock an "outperform" rating in a report on Thursday, June 5th. The Goldman Sachs Group lifted their target price on HealthEquity from $94.00 to $104.00 and gave the stock a "neutral" rating in a report on Wednesday, June 4th. JMP Securities lifted their target price on HealthEquity from $110.00 to $117.00 and gave the stock a "market outperform" rating in a report on Wednesday, June 4th. Raymond James Financial restated a "strong-buy" rating and issued a $120.00 target price (up from $115.00) on shares of HealthEquity in a report on Tuesday. Finally, Royal Bank Of Canada lifted their price target on HealthEquity from $112.00 to $117.00 and gave the company an "outperform" rating in a report on Wednesday, June 4th. One equities research analyst has rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $118.55.

Get Our Latest Report on HQY

HealthEquity Company Profile

(Free Report)

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.

Read More

Institutional Ownership by Quarter for HealthEquity (NASDAQ:HQY)

Should You Invest $1,000 in HealthEquity Right Now?

Before you consider HealthEquity, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HealthEquity wasn't on the list.

While HealthEquity currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Don’t Miss These Top 3 Defense Stocks Set To Gain
Triple-Digit Gains: These 4 Nuclear Stocks Have Even More Upside Ahead
3 Made in America Stocks Under $20 You Need to See!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines